Critical Analysis: MannKind (MNKD) vs. Its Peers
MannKind (NASDAQ: MNKD) is one of 307 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare MannKind to related companies based on the strength of its profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.
Volatility and Risk
MannKind has a beta of 3.1, indicating that its share price is 210% more volatile than the S&P 500. Comparatively, MannKind’s rivals have a beta of 1.83, indicating that their average share price is 83% more volatile than the S&P 500.
This table compares MannKind and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares MannKind and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|MannKind||$174.76 million||$125.66 million||2.41|
|MannKind Competitors||$290.00 million||$35.57 million||156.26|
MannKind’s rivals have higher revenue, but lower earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a summary of current recommendations for MannKind and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
MannKind currently has a consensus price target of $0.92, suggesting a potential downside of 71.67%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 37.05%. Given MannKind’s rivals stronger consensus rating and higher possible upside, analysts clearly believe MannKind has less favorable growth aspects than its rivals.
Insider and Institutional Ownership
14.7% of MannKind shares are held by institutional investors. Comparatively, 50.1% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 1.6% of MannKind shares are held by insiders. Comparatively, 16.4% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
MannKind rivals beat MannKind on 9 of the 13 factors compared.
MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company’s fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.
Receive News & Ratings for MannKind Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind Co. and related companies with MarketBeat.com's FREE daily email newsletter.